Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer
- PMID: 27249683
- DOI: 10.1200/EDBK_159069
Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer
Abstract
For the hundreds of thousands of premenopausal women who are diagnosed annually with endocrine-sensitive breast cancer, treatment strategies are complex. For many, chemotherapy may not be necessary, and endocrine therapy decision making is paramount. Options for adjuvant endocrine regimens include tamoxifen for 5 years, tamoxifen for 10 years, ovarian function suppression (OFS) plus tamoxifen for 5 years, and OFS plus an aromatase inhibitor for 5 years. There are modest differences in efficacy between these regimens, with a benefit from OFS most obvious among patients with higher-risk disease; therefore, choosing which should be used for a given patient requires consideration of expected toxicities and patient preferences. An aromatase inhibitor cannot be safely prescribed without OFS in this setting. Additional research is needed to determine whether genomic tests such as Prosigna and Endopredict can help with decision making about optimal duration of endocrine therapy for premenopausal patients. Endocrine therapy side effects can include hot flashes, sexual dysfunction, osteoporosis, and infertility, all of which may impair quality of life and can encourage nonadherence with treatment. Ovarian function suppression worsens menopausal side effects. Hot flashes tend to be worse with tamoxifen/OFS, whereas sexual dysfunction and osteoporosis tend to be worse with aromatase inhibitors/OFS. Pregnancy is safe after endocrine therapy, and some survivors can conceive naturally. Still, embryo or oocyte cryopreservation should be considered at the time of diagnosis for patients with endocrine-sensitive disease who desire future childbearing, particularly if they will undergo chemotherapy.
Similar articles
-
Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.Drugs. 2015 Aug;75(12):1311-21. doi: 10.1007/s40265-015-0433-7. Drugs. 2015. PMID: 26177891 Review.
-
Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.Breast. 2015 Nov;24 Suppl 2:S120-5. doi: 10.1016/j.breast.2015.07.027. Breast. 2015. PMID: 26255743 Review.
-
Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.Breast. 2019 Nov;48 Suppl 1:S85-S88. doi: 10.1016/S0960-9776(19)31131-2. Breast. 2019. PMID: 31839169
-
The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?Cancer Treat Rev. 2013 Dec;39(8):886-90. doi: 10.1016/j.ctrv.2013.04.007. Epub 2013 May 29. Cancer Treat Rev. 2013. PMID: 23725877 Review.
-
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.J Clin Oncol. 2017 Sep 20;35(27):3113-3122. doi: 10.1200/JCO.2016.72.0946. Epub 2017 Jun 27. J Clin Oncol. 2017. PMID: 28654365 Free PMC article.
Cited by
-
Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- Early Breast Cancer.J Pers Med. 2021 Aug 25;11(9):835. doi: 10.3390/jpm11090835. J Pers Med. 2021. PMID: 34575612 Free PMC article.
-
A tissue microRNA signature that predicts the prognosis of breast cancer in young women.PLoS One. 2017 Nov 15;12(11):e0187638. doi: 10.1371/journal.pone.0187638. eCollection 2017. PLoS One. 2017. PMID: 29141042 Free PMC article.
-
Clinical utility of genomic signatures in young breast cancer patients: a systematic review.NPJ Breast Cancer. 2020 Sep 25;6:46. doi: 10.1038/s41523-020-00188-3. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 33062888 Free PMC article. Review.
-
Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.Curr Treat Options Oncol. 2017 Jan;18(1):4. doi: 10.1007/s11864-017-0442-8. Curr Treat Options Oncol. 2017. PMID: 28185173 Review.
-
Distinct clinicopathological features and treatment differences in breast cancer patients of young age.Sci Rep. 2025 Feb 15;15(1):5655. doi: 10.1038/s41598-025-90053-9. Sci Rep. 2025. PMID: 39955428 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical